
We are proud to announce that Amyl Therapeutics was the one of the 10 startups selected to pitch at the BioVaria conference in Munich on April 28, 2025.
Our presentation was focus on our innovative technology, which we believe has the potential to transform the neurodegenerative research sector.
Thank you to the BioVaria team for this opportunity !